{"protocolSection":{"identificationModule":{"nctId":"NCT02788045","orgStudyIdInfo":{"id":"CR108152"},"secondaryIdInfos":[{"id":"VAC89220HPX2004","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults","officialTitle":"A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess the Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens; Priming With Trivalent Ad26.Mos.HIV and Boosting With Trivalent Ad26.Mos.HIV And Clade C Gp140 Plus Adjuvant or Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Clade C Gp140 Plus Adjuvant"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-07-08","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-04-25","type":"ACTUAL"},"completionDateStruct":{"date":"2022-04-25","type":"ACTUAL"},"studyFirstSubmitDate":"2016-05-27","studyFirstSubmitQcDate":"2016-05-27","studyFirstPostDateStruct":{"date":"2016-06-02","type":"ESTIMATED"},"resultsFirstSubmitDate":"2023-04-25","resultsFirstSubmitQcDate":"2023-06-08","resultsFirstPostDateStruct":{"date":"2023-06-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-22","lastUpdatePostDateStruct":{"date":"2025-05-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens of priming with trivalent Ad26.Mos.HIV and boosting with trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or priming with tetravalent Ad26.Mos4.HIV and boosting with Ad26.Mos4.HIV and Clade C glycoprotein (gp)140 plus adjuvant. Immune responses of the different vaccine schedules will be assessed."},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":201,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1A: Ad26.Mos.HIV","type":"EXPERIMENTAL","description":"Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12, followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.","interventionNames":["Biological: Ad26.Mos.HIV","Biological: Clade C gp140"]},{"label":"Group 1B: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive placebo at Weeks 0, 12, 24 and 48.","interventionNames":["Drug: Placebo"]},{"label":"Group 2A: Ad26.Mos4.HIV","type":"EXPERIMENTAL","description":"Participants will receive Ad26.Mos4.HIV vaccine at Week 0 and 12; followed by Ad26.Mos4.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48. Participants will be included in an optional Long-term Extension (LTE) phase (3 years or 4 years Follow-up after Week 72, every 6 months visit) to assess immunogenicity and safety (serious adverse events \\[SAEs\\]).","interventionNames":["Biological: Ad26.Mos4.HIV","Biological: Clade C gp140"]},{"label":"Group 2B: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive placebo at Weeks 0, 12, 24 and 48.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.Mos.HIV","description":"Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\\*10\\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.","armGroupLabels":["Group 1A: Ad26.Mos.HIV"]},{"type":"BIOLOGICAL","name":"Ad26.Mos4.HIV","description":"Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\\*10\\^10 viral particle per 0.5mL injection administered intramuscularly.","armGroupLabels":["Group 2A: Ad26.Mos4.HIV"]},{"type":"BIOLOGICAL","name":"Clade C gp140","description":"Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.","armGroupLabels":["Group 1A: Ad26.Mos.HIV","Group 2A: Ad26.Mos4.HIV"]},{"type":"DRUG","name":"Placebo","description":"Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.","armGroupLabels":["Group 1B: Placebo","Group 2B: Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Solicited Local Adverse Events (AEs) Post First Vaccination","description":"Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.","timeFrame":"7 days after first vaccination on Day 1 (Day 8)"},{"measure":"Percentage of Participants With Solicited Local AEs Post Second Vaccination","description":"Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.","timeFrame":"7 days after second vaccination on Day 85 (Day 92)"},{"measure":"Percentage of Participants With Solicited Local AEs Post Third Vaccination","description":"Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.","timeFrame":"7 days after third vaccination on Day 169 (Day 176)"},{"measure":"Percentage of Participants With Solicited Local AEs Post Fourth Vaccination","description":"Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.","timeFrame":"7 days after fourth vaccination on Day 337 (Day 344)"},{"measure":"Percentage of Participants With Solicited Systemic AEs Post First Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination.","timeFrame":"7 days after first vaccination on Day 1 (Day 8)"},{"measure":"Percentage of Participants With Solicited Systemic AEs Post Second Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination.","timeFrame":"7 days after second vaccination on Day 85 (Day 92)"},{"measure":"Percentage of Participants With Solicited Systemic AEs Post Third Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination.","timeFrame":"7 days after third vaccination on Day 169 (Day 176)"},{"measure":"Percentage of Participants With Solicited Systemic AEs Post Fourth Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination.","timeFrame":"7 days after fourth vaccination on Day 337 (Day 344)"},{"measure":"Percentage of Participants With Unsolicited AEs for 28 Days After First Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as \"solicited AEs\" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days.","timeFrame":"28 days after first vaccination on Day 1 (Day 29)"},{"measure":"Percentage of Participants With Unsolicited AEs for 28 Days After Second Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as \"solicited AEs\" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days.","timeFrame":"28 days after second vaccination on Day 85 (Day 113)"},{"measure":"Percentage of Participants With Unsolicited AEs for 28 Days After Third Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as \"solicited AEs\" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days.","timeFrame":"28 days after third vaccination on Day 169 (Day 197)"},{"measure":"Percentage of Participants With Unsolicited AEs for 28 Days After Fourth Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as \"solicited AEs\" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days.","timeFrame":"28 days after fourth vaccination on Day 334 (Day 362)"},{"measure":"Percentage of Participants With Discontinuations From Vaccination Due to AEs","description":"Percentage of participants with discontinuations from vaccination due to AEs were reported.","timeFrame":"Up to Week 72"},{"measure":"Percentage of Participants With Serious Adverse Events (SAEs) During Main Study","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. SAE was defined as any AE that resulted in: death, persistent or significant disability/incapacity, required inpatient hospitalization or prolongation of existing hospitalization, was life-threatening experience, was a congenital anomaly/birth defect and would jeopardize participant and/or required medical or surgical intervention to prevent one of the outcomes listed above.","timeFrame":"Up to Week 72"},{"measure":"Percentage of Participants With SAEs During Long Term Extension (LTE) Period","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. SAE was defined as any AE that resulted in: death, persistent or significant disability/incapacity, required inpatient hospitalization or prolongation of existing hospitalization, was life-threatening experience, was a congenital anomaly/birth defect and would jeopardize participant and/or required medical or surgical intervention to prevent one of the outcomes listed above. This outcome measure was planned to be analyzed for specified arm only.","timeFrame":"From Week 96 to Week 264"},{"measure":"Percentage of Participants With AEs of Special Interest During Main Study","description":"Percentage of participants with AEs of special interest during main study were reported. HIV infection was considered as an AE of special interest.","timeFrame":"Up to Week 72"},{"measure":"Percentage of Participants With AEs of Special Interest During LTE Period","description":"Percentage of participants with AEs of special interest during LTE period were reported. HIV infection was considered as an AE of special interest. This outcome measure was planned to be analyzed for specified arm only.","timeFrame":"From Week 96 to Week 264"},{"measure":"Percentage of Responders for Envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) Specific Binding Antibody Titers at Week 28","description":"Percentage of responders for envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) specific binding antibody titers at Week 28 were reported. Env Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012)-specific binding antibody titers were assessed using enzyme-linked immunosorbent assay (ELISA). The response was defined as post-baseline value greater than (\\>) lower limit of quantification (LLOQ) if baseline value less than (\\<) LLOQ or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline value greater than or equal to (\\>=) LLOQ.","timeFrame":"Week 28"},{"measure":"Percentage of Responders for Envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) Specific Binding Antibody Titers at Week 52","description":"Percentage of responders for envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) specific binding antibody titers at Week 52 were reported. Env Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012)-specific binding antibody titers were assessed using enzyme-linked immunosorbent assay (ELISA). The response was defined as post-baseline value greater than (\\>) lower limit of quantification (LLOQ) if baseline value less than (\\<) LLOQ or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline value greater than or equal to (\\>=) LLOQ.","timeFrame":"Week 52"},{"measure":"Percentage of Responders for Envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) Specific Binding Antibody Titers at Week 72","description":"Percentage of responders for envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) specific binding antibody titers at Week 72 were reported. Env Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012)-specific binding antibody titers were assessed using enzyme-linked immunosorbent assay (ELISA). The response was defined as post-baseline value greater than (\\>) lower limit of quantification (LLOQ) if baseline value less than (\\<) LLOQ or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline value greater than or equal to (\\>=) LLOQ.","timeFrame":"Week 72"}],"secondaryOutcomes":[{"measure":"Percentage of Responders for Human Immunodeficiency Virus Neutralizing Antibody (HIV nAb)","description":"The functionality of vaccine-induced antibody responses was investigated by the determination of nAb activity in a virus neutralization assay (VNA) using TZM-bl cells and Env-pseudotyped viruses. The response was defined as post-baseline value \\>LLOQ. The LLOQ for this assay was an inhibitory concentration (IC50) of 20 (fold-dilution). The data was collected for the responses against Tier 1 HIV strain Clade C (MW965.26 and C97ZA.012).","timeFrame":"Weeks 28, 52 and 72"},{"measure":"Percentage of Responders for Env Antibody-dependent Cellular Phagocytosis (ADCP) gp Antibody","description":"The functionality of vaccine-induced antibody responses was investigated by the determination of ADCP. The response was defined as post-baseline value \\> limit of detection (LOD) if baseline value \\<LOD or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline value \\>=LOD. The lower limits of detection (LODs) for this assay were 5.16, 6.43, 6.49, 4.32 and 4.28 (phagocytic score) for Clade A (92UG037.1), Clade B (1990a), Clade C (Con C), Clade C (C97ZA.012), and Mos1, respectively.","timeFrame":"Weeks 28, 52 and 72"},{"measure":"Percentage of Responders With Interferon-gamma (IFN-gamma) T Cell Responses Assessed Using Enzyme-linked Immunospot Assay (ELISpot)","description":"Frozen peripheral blood mononuclear cell (PBMCs) were analyzed by interferon-gamma (IFN-gamma) (ELISpot). The response was defined as post-baseline value \\>P95 if baseline \\<P95 or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline \\>=P95.","timeFrame":"Weeks 26, 52 and 72"},{"measure":"Percentage of Responders for Immunoglobulin G1 (IgG1) and IgG3 Gylcoprotein (gp) 140 Binding Antibody Assessed Using Clade C (C97ZA.012) Env Enzyme-linked Immunosorbent Assay (ELISA)","description":"Vaccine-induced binding antibody IgG1 and IgG3 subclass responses were investigated using Clade C (C97ZA.012) specific ELISAs. The response was defined as post-baseline value \\>LLOQ if baseline \\<LLOQ or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline \\>=LLOQ. The LLOQs for this assay were 12.3 and 12.4 for IgG1 and IgG3, respectively.","timeFrame":"Weeks 28, 52 and 72"},{"measure":"Percentage of Responders for CD4+ and CD8+ T-Cell Responses","description":"Intracellular cytokine staining (ICS) was performed to examine the type of T-cell responding to vaccination. Responder definition was based on the Fisher's exact text between cytokine producing cells and non-producing cells in stimulated versus non-stimulated conditions.","timeFrame":"Weeks 28, 52 and 72"},{"measure":"Percentage of Participants With T-cell Development","description":"As per change in planned analysis, this outcome measure was not performed since it was no longer considered relevant to interpret the immunogenicity of the vaccines.","timeFrame":"Up to Week 264"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Are negative for human immunodeficiency virus (HIV) infection at screening\n* Is healthy on the basis of physical examination, medical history, electrocardiogram (ECG), and vital signs measurement performed at screening\n* Are willing/able to adhere to the prohibitions and restrictions specified in the protocol and study procedures\n* Female participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin \\[beta hCG\\]) at the Screening visit, and a negative urine pregnancy test pre-dose on Day 1\n* Are assessed by the clinic staff as being at low risk for HIV infection\n\nExclusion Criteria:\n\n* Has chronic hepatitis B (measured by hepatitis B surface antigen test) or active hepatitis C (measured by hepatitis C virus \\[HCV\\] Ab test; if positive, HCV ribonucleic acid \\[RNA\\] PCR test will be used to confirm active versus past HCV infection), active syphilis infection, chlamydia, gonorrhea, or trichomonas . Active syphilis documented by serology unless positive serology is due to past treated infection\n* Has had a thyroidectomy or active thyroid disease requiring medication during the last 12 months (not excluded: a stable thyroid supplementation)\n* Has had major psychiatric illness and/or substance abuse problems during the past 12 months (including hospitalization or periods of work disability) that in the opinion of the investigator would preclude participation\n* Has been in receipt of any licensed vaccine within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination\n* Is a recipient of a prophylactic or therapeutic HIV vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months prior to the Day 1 visit (Vaccination 1). For participants who received an experimental vaccine (except HIV vaccine) more than 12 months prior to the Day 1 visit (Vaccination 1), documentation of the identity of the experimental vaccine must be provided to the sponsor, who will determine eligibility on a case-by-case basis","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Birmingham","state":"Alabama","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"city":"San Francisco","state":"California","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"city":"Decatur","state":"Georgia","country":"United States","geoPoint":{"lat":33.77483,"lon":-84.29631}},{"city":"Silver Spring","state":"Maryland","country":"United States","geoPoint":{"lat":38.99067,"lon":-77.02609}},{"city":"Boston","state":"Massachusetts","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"city":"New York","state":"New York","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"city":"Rochester","state":"New York","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"city":"Philadelphia","state":"Pennsylvania","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"city":"Seattle","state":"Washington","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"city":"Kigali","country":"Rwanda","geoPoint":{"lat":-1.94995,"lon":30.05885}}]},"referencesModule":{"references":[{"pmid":"33010242","type":"DERIVED","citation":"Baden LR, Stieh DJ, Sarnecki M, Walsh SR, Tomaras GD, Kublin JG, McElrath MJ, Alter G, Ferrari G, Montefiori D, Mann P, Nijs S, Callewaert K, Goepfert P, Edupuganti S, Karita E, Langedijk JP, Wegmann F, Corey L, Pau MG, Barouch DH, Schuitemaker H, Tomaka F; Traverse/HVTN 117/HPX2004 Study Team. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV. 2020 Oct;7(10):e688-e698. doi: 10.1016/S2352-3018(20)30229-0."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 201 participants were enrolled, out of which 198 participants were randomized and vaccinated; 3 participants were not vaccinated and hence were not included in analyses.","groups":[{"id":"FG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"FG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"FG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"periods":[{"title":"Main Study (Up to Week 72)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"110"},{"groupId":"FG001","numSubjects":"55"},{"groupId":"FG002","numSubjects":"33"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"94"},{"groupId":"FG001","numSubjects":"45"},{"groupId":"FG002","numSubjects":"28"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Long Term Extension (From Wk 72 to 264)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Only eligible participants entered LTE phase.","numSubjects":"77"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"BG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"BG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"198"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28.0","lowerLimit":"18","upperLimit":"50"},{"groupId":"BG001","value":"27.0","lowerLimit":"19","upperLimit":"50"},{"groupId":"BG002","value":"27.0","lowerLimit":"18","upperLimit":"44"},{"groupId":"BG003","value":"27.0","lowerLimit":"18","upperLimit":"50"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"110"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"88"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"23"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"96"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"173"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"10"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"60"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"105"}]}]},{"title":"More than one race","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"13"}]}]},{"title":"Unknown or Not Reported","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"6"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"RWANDA","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"17"}]}]},{"title":"UNITED STATES","categories":[{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"181"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Solicited Local Adverse Events (AEs) Post First Vaccination","description":"Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.","populationDescription":"The full analysis set (FAS) included all participants who were randomized and who received at least one dose of study vaccine.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"7 days after first vaccination on Day 1 (Day 8)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.9"},{"groupId":"OG001","value":"78.2"},{"groupId":"OG002","value":"27.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Local AEs Post Second Vaccination","description":"Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.","populationDescription":"The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"7 days after second vaccination on Day 85 (Day 92)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3"},{"groupId":"OG001","value":"76.5"},{"groupId":"OG002","value":"50"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Local AEs Post Third Vaccination","description":"Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.","populationDescription":"The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"7 days after third vaccination on Day 169 (Day 176)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8"},{"groupId":"OG001","value":"79.6"},{"groupId":"OG002","value":"21.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Local AEs Post Fourth Vaccination","description":"Solicited local AEs were predefined local events (at the injection site: erythema, induration, swelling, itching and warmth) that were by definition considered as related to the study vaccine and collected within 7 days after vaccination.","populationDescription":"The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"7 days after fourth vaccination on Day 337 (Day 344)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"68.9"},{"groupId":"OG002","value":"29.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Systemic AEs Post First Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination.","populationDescription":"FAS included all participants who were randomized and who received at least one dose of study vaccine.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"7 days after first vaccination on Day 1 (Day 8)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.1"},{"groupId":"OG001","value":"83.6"},{"groupId":"OG002","value":"54.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Systemic AEs Post Second Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination.","populationDescription":"FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"7 days after second vaccination on Day 85 (Day 92)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"54.9"},{"groupId":"OG002","value":"40.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Systemic AEs Post Third Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination.","populationDescription":"FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"7 days after third vaccination on Day 169 (Day 176)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6"},{"groupId":"OG001","value":"44.9"},{"groupId":"OG002","value":"34.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Systemic AEs Post Fourth Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Solicited systemic AEs including pyrexia/fever, headache, fatigue, myalgia, nausea and chills were collected within 7 days after vaccination.","populationDescription":"FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"7 days after fourth vaccination on Day 337 (Day 344)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5"},{"groupId":"OG001","value":"53.3"},{"groupId":"OG002","value":"33.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Unsolicited AEs for 28 Days After First Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as \"solicited AEs\" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days.","populationDescription":"The FAS included all participants who were randomized and who received at least one dose of study vaccine.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"28 days after first vaccination on Day 1 (Day 29)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2"},{"groupId":"OG001","value":"41.8"},{"groupId":"OG002","value":"30.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Unsolicited AEs for 28 Days After Second Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as \"solicited AEs\" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days.","populationDescription":"The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"28 days after second vaccination on Day 85 (Day 113)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4"},{"groupId":"OG001","value":"23.5"},{"groupId":"OG002","value":"37.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Unsolicited AEs for 28 Days After Third Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as \"solicited AEs\" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days.","populationDescription":"The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"28 days after third vaccination on Day 169 (Day 197)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"32"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3"},{"groupId":"OG001","value":"20.4"},{"groupId":"OG002","value":"21.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Unsolicited AEs for 28 Days After Fourth Vaccination","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. Unsolicited AEs were defined as the AEs other than those categorized as \"solicited AEs\" and were required to be collected for any events that occurred from the time of vaccination and through the subsequent 28 days.","populationDescription":"The FAS included all participants who were randomized and who received at least one dose of study vaccine. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"28 days after fourth vaccination on Day 334 (Day 362)","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.2"},{"groupId":"OG001","value":"22.2"},{"groupId":"OG002","value":"40.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Discontinuations From Vaccination Due to AEs","description":"Percentage of participants with discontinuations from vaccination due to AEs were reported.","populationDescription":"The FAS included all participants who were randomized and who received at least one dose of study vaccine.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to Week 72","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1.8"},{"groupId":"OG002","value":"6.1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) During Main Study","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. SAE was defined as any AE that resulted in: death, persistent or significant disability/incapacity, required inpatient hospitalization or prolongation of existing hospitalization, was life-threatening experience, was a congenital anomaly/birth defect and would jeopardize participant and/or required medical or surgical intervention to prevent one of the outcomes listed above.","populationDescription":"The FAS included all participants who were randomized and who received at least one dose of study vaccine.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to Week 72","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With SAEs During Long Term Extension (LTE) Period","description":"An AE was defined as any untoward medical event that occurred in a participant administered an investigational product, and it did not necessarily indicated only events with clear causal relationship with the relevant investigational product. SAE was defined as any AE that resulted in: death, persistent or significant disability/incapacity, required inpatient hospitalization or prolongation of existing hospitalization, was life-threatening experience, was a congenital anomaly/birth defect and would jeopardize participant and/or required medical or surgical intervention to prevent one of the outcomes listed above. This outcome measure was planned to be analyzed for specified arm only.","populationDescription":"The FAS included all participants those were all the participants from the Tetravalent Ad26.Mos4.HIV group who had received all 4 vaccinations and were negative for HIV infections at Week 72.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Week 96 to Week 264","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With AEs of Special Interest During Main Study","description":"Percentage of participants with AEs of special interest during main study were reported. HIV infection was considered as an AE of special interest.","populationDescription":"The FAS included all participants who were randomized and who received at least one dose of study vaccine.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to Week 72","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With AEs of Special Interest During LTE Period","description":"Percentage of participants with AEs of special interest during LTE period were reported. HIV infection was considered as an AE of special interest. This outcome measure was planned to be analyzed for specified arm only.","populationDescription":"The FAS included all participants those were all the participants from the Tetravalent Ad26.Mos4.HIV group who had received all 4 vaccinations and were negative for HIV infections at Week 72.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Week 96 to Week 264","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Responders for Envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) Specific Binding Antibody Titers at Week 28","description":"Percentage of responders for envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) specific binding antibody titers at Week 28 were reported. Env Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012)-specific binding antibody titers were assessed using enzyme-linked immunosorbent assay (ELISA). The response was defined as post-baseline value greater than (\\>) lower limit of quantification (LLOQ) if baseline value less than (\\<) LLOQ or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline value greater than or equal to (\\>=) LLOQ.","populationDescription":"The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of responders","timeFrame":"Week 28","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"classes":[{"title":"Clade A (92UG037.1)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.3","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"92.6","upperLimit":"100.0"},{"groupId":"OG002","value":"19.4","lowerLimit":"7.5","upperLimit":"37.5"}]}]},{"title":"Clade B (1990a)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.3","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"92.6","upperLimit":"100.0"},{"groupId":"OG002","value":"12.9","lowerLimit":"3.6","upperLimit":"29.8"}]}]},{"title":"Clade C (Con C)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.2","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"92.6","upperLimit":"100"},{"groupId":"OG002","value":"12.9","lowerLimit":"3.6","upperLimit":"29.8"}]}]},{"title":"Clade C (C97ZA.012)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.3","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"92.6","upperLimit":"100"},{"groupId":"OG002","value":"6.5","lowerLimit":"0.8","upperLimit":"21.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Responders for Envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) Specific Binding Antibody Titers at Week 52","description":"Percentage of responders for envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) specific binding antibody titers at Week 52 were reported. Env Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012)-specific binding antibody titers were assessed using enzyme-linked immunosorbent assay (ELISA). The response was defined as post-baseline value greater than (\\>) lower limit of quantification (LLOQ) if baseline value less than (\\<) LLOQ or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline value greater than or equal to (\\>=) LLOQ.","populationDescription":"The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of responders","timeFrame":"Week 52","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"classes":[{"title":"Clade A (92UG037.1)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.1","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"91.2","upperLimit":"100.0"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade B (1990a)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.1","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"91.2","upperLimit":"100"},{"groupId":"OG002","value":"22.2","lowerLimit":"8.6","upperLimit":"42.3"}]}]},{"title":"Clade C (Con C)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.1","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"91.2","upperLimit":"100"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (C97ZA.012)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.1","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"91.2","upperLimit":"100"},{"groupId":"OG002","value":"3.7","lowerLimit":"0.1","upperLimit":"19.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Responders for Envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) Specific Binding Antibody Titers at Week 72","description":"Percentage of responders for envelop (Env) Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012) specific binding antibody titers at Week 72 were reported. Env Clade A (92UG037.1), B (1990a), and C (Con C), (C97ZA.012)-specific binding antibody titers were assessed using enzyme-linked immunosorbent assay (ELISA). The response was defined as post-baseline value greater than (\\>) lower limit of quantification (LLOQ) if baseline value less than (\\<) LLOQ or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline value greater than or equal to (\\>=) LLOQ.","populationDescription":"The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of responders","timeFrame":"Week 72","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"classes":[{"title":"Clade A (92UG037.1)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.1","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"91.8","upperLimit":"100.0"},{"groupId":"OG002","value":"2","lowerLimit":"0.9","upperLimit":"24.3"}]}]},{"title":"Clade B (1990a)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.1","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"91.8","upperLimit":"100"},{"groupId":"OG002","value":"11.1","lowerLimit":"2.4","upperLimit":"29.2"}]}]},{"title":"Clade C (Con C)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"91.8","upperLimit":"100"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (C97ZA.012)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.1","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"91.8","upperLimit":"100"},{"groupId":"OG002","value":"3.7","lowerLimit":"0.1","upperLimit":"19"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders for Human Immunodeficiency Virus Neutralizing Antibody (HIV nAb)","description":"The functionality of vaccine-induced antibody responses was investigated by the determination of nAb activity in a virus neutralization assay (VNA) using TZM-bl cells and Env-pseudotyped viruses. The response was defined as post-baseline value \\>LLOQ. The LLOQ for this assay was an inhibitory concentration (IC50) of 20 (fold-dilution). The data was collected for the responses against Tier 1 HIV strain Clade C (MW965.26 and C97ZA.012).","populationDescription":"The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of responders","timeFrame":"Weeks 28, 52 and 72","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"30"}]}],"classes":[{"title":"Clade C (MW965.26) Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"94.4","upperLimit":"100.0"},{"groupId":"OG001","value":"66.7","lowerLimit":"51.6","upperLimit":"79.6"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (MW965.26) Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.1","upperLimit":"100.0"},{"groupId":"OG001","value":"90","lowerLimit":"76.3","upperLimit":"97.2"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (MW965.26) Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","lowerLimit":"94.1","upperLimit":"100.0"},{"groupId":"OG001","value":"100","lowerLimit":"85.8","upperLimit":"100.0"}]}]},{"title":"Clade C (C97ZA.012) Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (C97ZA.012) Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders for Env Antibody-dependent Cellular Phagocytosis (ADCP) gp Antibody","description":"The functionality of vaccine-induced antibody responses was investigated by the determination of ADCP. The response was defined as post-baseline value \\> limit of detection (LOD) if baseline value \\<LOD or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline value \\>=LOD. The lower limits of detection (LODs) for this assay were 5.16, 6.43, 6.49, 4.32 and 4.28 (phagocytic score) for Clade A (92UG037.1), Clade B (1990a), Clade C (Con C), Clade C (C97ZA.012), and Mos1, respectively.","populationDescription":"The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of responders","timeFrame":"Weeks 28, 52 and 72","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"31"}]}],"classes":[{"title":"Clade A (92UG037.1) at Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","lowerLimit":"62.5","upperLimit":"81"},{"groupId":"OG001","value":"36.2","lowerLimit":"22.7","upperLimit":"51.5"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade B (1990a) at Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.4","lowerLimit":"59.3","upperLimit":"78.3"},{"groupId":"OG001","value":"57.4","lowerLimit":"42.2","upperLimit":"71.7"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (Con C) at Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","lowerLimit":"80.8","upperLimit":"94.3"},{"groupId":"OG001","value":"66","lowerLimit":"50.7","upperLimit":"79.1"},{"groupId":"OG002","value":"16.1","lowerLimit":"5.5","upperLimit":"33.7"}]}]},{"title":"Mos1 at Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"96.3","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"92.5","upperLimit":"100"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (C97ZA.012) at Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98","lowerLimit":"92.8","upperLimit":"99.8"},{"groupId":"OG001","value":"93.6","lowerLimit":"82.5","upperLimit":"98.7"},{"groupId":"OG002","value":"3.2","lowerLimit":"0.1","upperLimit":"16.7"}]}]},{"title":"Clade C (C97ZA.012) at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","lowerLimit":"92.4","upperLimit":"99.7"},{"groupId":"OG001","value":"82.5","lowerLimit":"67.2","upperLimit":"92.7"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (C97ZA.012) at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","lowerLimit":"94.1","upperLimit":"100"},{"groupId":"OG001","value":"97.7","lowerLimit":"87.7","upperLimit":"99.9"},{"groupId":"OG002","value":"18.5","lowerLimit":"6.3","upperLimit":"38.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders With Interferon-gamma (IFN-gamma) T Cell Responses Assessed Using Enzyme-linked Immunospot Assay (ELISpot)","description":"Frozen peripheral blood mononuclear cell (PBMCs) were analyzed by interferon-gamma (IFN-gamma) (ELISpot). The response was defined as post-baseline value \\>P95 if baseline \\<P95 or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline \\>=P95.","populationDescription":"The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of responders","timeFrame":"Weeks 26, 52 and 72","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"classes":[{"title":"ENV peptide pool potential T-cell epitope (PTE) at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96","lowerLimit":"90.0","upperLimit":"98.9"},{"groupId":"OG001","value":"79.2","lowerLimit":"65","upperLimit":"89.5"},{"groupId":"OG002","value":"3.2","lowerLimit":"0.1","upperLimit":"16.7"}]}]},{"title":"ENV peptide pool PTE at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","lowerLimit":"89.2","upperLimit":"98.8"},{"groupId":"OG001","value":"85","lowerLimit":"70.2","upperLimit":"94.3"},{"groupId":"OG002","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"}]}]},{"title":"ENV peptide pool PTE at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","lowerLimit":"92.1","upperLimit":"99.7"},{"groupId":"OG001","value":"83.3","lowerLimit":"68.6","upperLimit":"93"},{"groupId":"OG002","value":"3.7","lowerLimit":"0.1","upperLimit":"19"}]}]},{"title":"ENV peptide pool Mos1 at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96","lowerLimit":"90","upperLimit":"98.9"},{"groupId":"OG001","value":"87.5","lowerLimit":"74.8","upperLimit":"95.3"},{"groupId":"OG002","value":"6.5","lowerLimit":"0.8","upperLimit":"21.4"}]}]},{"title":"ENV peptide pool Mos1 at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","lowerLimit":"94.1","upperLimit":"100"},{"groupId":"OG001","value":"92.5","lowerLimit":"79.6","upperLimit":"98.4"},{"groupId":"OG002","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"}]}]},{"title":"ENV peptide pool Mos1 at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","lowerLimit":"92.1","upperLimit":"99.7"},{"groupId":"OG001","value":"92.9","lowerLimit":"80.5","upperLimit":"98.5"},{"groupId":"OG002","value":"18.5","lowerLimit":"6.3","upperLimit":"38.1"}]}]},{"title":"ENV peptide pool Mos2 at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96","lowerLimit":"90","upperLimit":"98.9"},{"groupId":"OG001","value":"58.3","lowerLimit":"43.2","upperLimit":"72.4"},{"groupId":"OG002","value":"3.2","lowerLimit":"0.1","upperLimit":"16.7"}]}]},{"title":"ENV peptide pool Mos2 at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","lowerLimit":"86.3","upperLimit":"97.6"},{"groupId":"OG001","value":"77.5","lowerLimit":"61.5","upperLimit":"89.2"},{"groupId":"OG002","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"}]}]},{"title":"ENV peptide pool Mos2 at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","lowerLimit":"88.9","upperLimit":"98.8"},{"groupId":"OG001","value":"70","lowerLimit":"53.5","upperLimit":"83.4"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Gag peptide pool PTE at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.6","lowerLimit":"48.2","upperLimit":"68.4"},{"groupId":"OG001","value":"60.4","lowerLimit":"45.3","upperLimit":"74.2"},{"groupId":"OG002","value":"3.2","lowerLimit":"0.1","upperLimit":"16.7"}]}]},{"title":"Gag peptide pool PTE at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57.6","lowerLimit":"46.9","upperLimit":"67.9"},{"groupId":"OG001","value":"70","lowerLimit":"53.5","upperLimit":"83.4"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Gag peptide pool PTE at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.6","lowerLimit":"31.2","upperLimit":"52.5"},{"groupId":"OG001","value":"47.6","lowerLimit":"32","upperLimit":"63.6"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Gag peptide pool Mos1 at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","lowerLimit":"49.3","upperLimit":"69.3"},{"groupId":"OG001","value":"54.2","lowerLimit":"39.2","upperLimit":"68.6"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Gag peptide pool Mos1 at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","lowerLimit":"50.1","upperLimit":"70.9"},{"groupId":"OG001","value":"60","lowerLimit":"43.3","upperLimit":"75.1"},{"groupId":"OG002","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"}]}]},{"title":"Gag peptide pool Mos1 at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","lowerLimit":"46.4","upperLimit":"67.7"},{"groupId":"OG001","value":"54.8","lowerLimit":"38.7","upperLimit":"70.2"},{"groupId":"OG002","value":"3.7","lowerLimit":"0.1","upperLimit":"19"}]}]},{"title":"Gag peptide pool Mos2 at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","lowerLimit":"59.6","upperLimit":"78.5"},{"groupId":"OG001","value":"60.4","lowerLimit":"45.3","upperLimit":"74.2"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Gag peptide pool Mos2 at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","lowerLimit":"54.6","upperLimit":"74.9"},{"groupId":"OG001","value":"62.5","lowerLimit":"45.8","upperLimit":"77.3"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Gag peptide pool Mos2 at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64","lowerLimit":"53.2","upperLimit":"73.9"},{"groupId":"OG001","value":"60","lowerLimit":"43.3","upperLimit":"75.1"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Pol peptide pool PTE at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","lowerLimit":"79.8","upperLimit":"93.6"},{"groupId":"OG001","value":"91.7","lowerLimit":"80","upperLimit":"97.7"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Pol peptide pool PTE at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","lowerLimit":"75.8","upperLimit":"91.4"},{"groupId":"OG001","value":"85","lowerLimit":"70.2","upperLimit":"94.3"},{"groupId":"OG002","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"}]}]},{"title":"Pol peptide pool PTE at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.6","lowerLimit":"79","upperLimit":"93.7"},{"groupId":"OG001","value":"90","lowerLimit":"76.3","upperLimit":"97.2"},{"groupId":"OG002","value":"11.1","lowerLimit":"2.4","upperLimit":"29.2"}]}]},{"title":"Pol peptide pool Mos1 at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","lowerLimit":"81.0","upperLimit":"94.3"},{"groupId":"OG001","value":"85.4","lowerLimit":"72.2","upperLimit":"93.9"},{"groupId":"OG002","value":"3.2","lowerLimit":"0.1","upperLimit":"16.7"}]}]},{"title":"Pol peptide pool Mos1 at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"82.6","lowerLimit":"73.3","upperLimit":"89.7"},{"groupId":"OG001","value":"92.5","lowerLimit":"79.6","upperLimit":"98.4"},{"groupId":"OG002","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"}]}]},{"title":"Pol peptide pool Mos1 at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","lowerLimit":"76.3","upperLimit":"92.0"},{"groupId":"OG001","value":"81","lowerLimit":"65.9","upperLimit":"91.4"},{"groupId":"OG002","value":"14.8","lowerLimit":"4.2","upperLimit":"33.7"}]}]},{"title":"Pol peptide pool Mos2 at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","lowerLimit":"86","upperLimit":"97.1"},{"groupId":"OG001","value":"93.8","lowerLimit":"82.8","upperLimit":"98.7"},{"groupId":"OG002","value":"3.2","lowerLimit":"0.1","upperLimit":"16.7"}]}]},{"title":"Pol peptide pool Mos2 at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","lowerLimit":"80.9","upperLimit":"94.7"},{"groupId":"OG001","value":"90","lowerLimit":"76.3","upperLimit":"97.2"},{"groupId":"OG002","value":"3.8","lowerLimit":"0.1","upperLimit":"19.6"}]}]},{"title":"Pol peptide pool Mos2 at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","lowerLimit":"81.7","upperLimit":"95.3"},{"groupId":"OG001","value":"92.5","lowerLimit":"79.6","upperLimit":"98.4"},{"groupId":"OG002","value":"7.4","lowerLimit":"0.9","upperLimit":"24.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders for Immunoglobulin G1 (IgG1) and IgG3 Gylcoprotein (gp) 140 Binding Antibody Assessed Using Clade C (C97ZA.012) Env Enzyme-linked Immunosorbent Assay (ELISA)","description":"Vaccine-induced binding antibody IgG1 and IgG3 subclass responses were investigated using Clade C (C97ZA.012) specific ELISAs. The response was defined as post-baseline value \\>LLOQ if baseline \\<LLOQ or missing or defined as post-baseline value \\>3-fold increase from baseline if baseline \\>=LLOQ. The LLOQs for this assay were 12.3 and 12.4 for IgG1 and IgG3, respectively.","populationDescription":"The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable for specified categories.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of responders","timeFrame":"Weeks 28, 52 and 72","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"29"}]}],"classes":[{"title":"Clade C (C97ZA.012) IgG1 at Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","lowerLimit":"62.6","upperLimit":"81.6"},{"groupId":"OG001","value":"61.4","lowerLimit":"45.5","upperLimit":"75.6"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (C97ZA.012) IgG1 at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","lowerLimit":"62.9","upperLimit":"81.8"},{"groupId":"OG001","value":"67.5","lowerLimit":"50.9","upperLimit":"81.4"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (C97ZA.012) IgG1 at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","lowerLimit":"56.4","upperLimit":"76.5"},{"groupId":"OG001","value":"50","lowerLimit":"34.2","upperLimit":"65.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (C97ZA.012) IgG3 at Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.4","lowerLimit":"56.8","upperLimit":"76.8"},{"groupId":"OG001","value":"18.2","lowerLimit":"8.2","upperLimit":"32.7"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (C97ZA.012) IgG3 at Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.3","lowerLimit":"55.7","upperLimit":"75.8"},{"groupId":"OG001","value":"46.2","lowerLimit":"30.1","upperLimit":"62.8"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"Clade C (C97ZA.012) IgG3 at Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.1","lowerLimit":"27.1","upperLimit":"48"},{"groupId":"OG001","value":"31","lowerLimit":"17.6","upperLimit":"47.1"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders for CD4+ and CD8+ T-Cell Responses","description":"Intracellular cytokine staining (ICS) was performed to examine the type of T-cell responding to vaccination. Responder definition was based on the Fisher's exact text between cytokine producing cells and non-producing cells in stimulated versus non-stimulated conditions.","populationDescription":"The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV during the study. Here 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure; 'n' (number analyzed) signifies number of participants evaluable at specified categories","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of responders","timeFrame":"Weeks 28, 52 and 72","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"31"}]}],"classes":[{"title":"CD4+ ENV pep pool (PP) (Mos1) IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.61","lowerLimit":"43.19","upperLimit":"63.80"},{"groupId":"OG001","value":"41.67","lowerLimit":"27.61","upperLimit":"56.79"},{"groupId":"OG002","value":"3.23","lowerLimit":"0.08","upperLimit":"16.70"}]}]},{"title":"CD4+ ENV PP (Mos1) IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.84","lowerLimit":"54.12","upperLimit":"74.56"},{"groupId":"OG001","value":"50.00","lowerLimit":"33.80","upperLimit":"66.20"}]}]},{"title":"CD4+ ENV PP (Mos1) IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.85","lowerLimit":"42.18","upperLimit":"65.21"},{"groupId":"OG001","value":"36.84","lowerLimit":"21.81","upperLimit":"54.01"}]}]},{"title":"CD4+ ENV PP (Mos1 ZA PTE) IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.70","lowerLimit":"46.25","upperLimit":"66.73"},{"groupId":"OG001","value":"43.75","lowerLimit":"29.48","upperLimit":"58.82"},{"groupId":"OG002","value":"3.23","lowerLimit":"0.08","upperLimit":"16.70"}]}]},{"title":"CD4+ ENV PP (Mos1 ZA PTE) IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.82","lowerLimit":"65.72","upperLimit":"84.19"},{"groupId":"OG001","value":"55","lowerLimit":"38.49","upperLimit":"70.74"}]}]},{"title":"CD4+ ENV PP (Mos1 ZA PTE) IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.10","lowerLimit":"52.44","upperLimit":"74.66"},{"groupId":"OG001","value":"36.84","lowerLimit":"21.81","upperLimit":"54.01"}]}]},{"title":"CD4+ ENV PP clade C (ZA) IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.39","lowerLimit":"36.20","upperLimit":"56.81"},{"groupId":"OG001","value":"18.75","lowerLimit":"8.95","upperLimit":"32.63"}]}]},{"title":"CD4+ ENV PP clade C (ZA) IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.74","lowerLimit":"52.99","upperLimit":"73.56"},{"groupId":"OG001","value":"35.00","lowerLimit":"20.63","upperLimit":"51.68"}]}]},{"title":"CD4+ ENV PP clade C (ZA) IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.28","lowerLimit":"39.69","upperLimit":"62.77"},{"groupId":"OG001","value":"10.53","lowerLimit":"2.94","upperLimit":"24.80"}]}]},{"title":"CD4+ ENV pol gag PP IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57.73","lowerLimit":"47.28","upperLimit":"67.70"},{"groupId":"OG001","value":"45.83","lowerLimit":"31.37","upperLimit":"60.83"},{"groupId":"OG002","value":"3.23","lowerLimit":"0.08","upperLimit":"16.70"}]}]},{"title":"CD4+ ENV pol gag PP IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.82","lowerLimit":"65.72","upperLimit":"84.19"},{"groupId":"OG001","value":"55","lowerLimit":"38.49","upperLimit":"70.74"}]}]},{"title":"CD4+ ENV pol gag PP IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.10","lowerLimit":"52.44","upperLimit":"74.66"},{"groupId":"OG001","value":"36.84","lowerLimit":"21.81","upperLimit":"54.01"}]}]},{"title":"CD4+ ENV gag PP ANY IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.25","lowerLimit":"3.63","upperLimit":"15.61"},{"groupId":"OG001","value":"6.25","lowerLimit":"1.31","upperLimit":"17.20"}]}]},{"title":"CD4+ ENV gag PP ANY IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.30","lowerLimit":"0.69","upperLimit":"9.33"},{"groupId":"OG001","value":"10.00","lowerLimit":"2.79","upperLimit":"23.66"}]}]},{"title":"CD4+ ENV gag PP ANY IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.56","lowerLimit":"0.31","upperLimit":"8.96"},{"groupId":"OG001","value":"5.26","lowerLimit":"0.64","upperLimit":"17.75"}]}]},{"title":"CD4+ ENV Pol PP (Mos1) IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.25","lowerLimit":"3.63","upperLimit":"15.61"},{"groupId":"OG001","value":"8.33","lowerLimit":"2.32","upperLimit":"19.98"}]}]},{"title":"CD4+ ENV Pol PP (Mos1) IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.59","lowerLimit":"2.46","upperLimit":"13.80"},{"groupId":"OG001","value":"7.50","lowerLimit":"1.57","upperLimit":"20.39"}]}]},{"title":"CD4+ ENV Pol PP (Mos1) IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.41","lowerLimit":"2.11","upperLimit":"14.33"},{"groupId":"OG001","value":"5.26","lowerLimit":"0.64","upperLimit":"17.75"}]}]},{"title":"CD8+ ENV PP (Mos1) IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.42","lowerLimit":"25.92","upperLimit":"45.84"},{"groupId":"OG001","value":"43.75","lowerLimit":"29.48","upperLimit":"58.82"}]}]},{"title":"CD8+ ENV PP (Mos1) IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.77","lowerLimit":"21.51","upperLimit":"41.32"},{"groupId":"OG001","value":"42.50","lowerLimit":"27.04","upperLimit":"59.11"}]}]},{"title":"CD8+ ENV PP (Mos1) IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.11","lowerLimit":"19.43","upperLimit":"40.42"},{"groupId":"OG001","value":"26.32","lowerLimit":"13.40","upperLimit":"43.10"}]}]},{"title":"CD8+ ENV PP (Mos1 ZA PTE) IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.67","lowerLimit":"31.68","upperLimit":"52.18"},{"groupId":"OG001","value":"45.83","lowerLimit":"31.37","upperLimit":"60.83"}]}]},{"title":"CD8+ ENV PP (Mos1 ZA PTE) IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.07","lowerLimit":"24.45","upperLimit":"44.75"},{"groupId":"OG001","value":"45.00","lowerLimit":"29.26","upperLimit":"61.51"}]}]},{"title":"CD8+ ENV PP (Mos1 ZA PTE) IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.18","lowerLimit":"23.87","upperLimit":"45.71"},{"groupId":"OG001","value":"28.95","lowerLimit":"15.42","upperLimit":"45.90"}]}]},{"title":"CD8+ ENV PP clade C (ZA) IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.88","lowerLimit":"14.08","upperLimit":"31.47"},{"groupId":"OG001","value":"22.92","lowerLimit":"12.03","upperLimit":"37.31"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"0"}]}]},{"title":"CD8+ ENV PP clade C (ZA) IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.38","lowerLimit":"8.67","upperLimit":"24.46"},{"groupId":"OG001","value":"17.50","lowerLimit":"7.34","upperLimit":"32.78"}]}]},{"title":"CD8+ ENV PP clade C (ZA) IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.46","lowerLimit":"9.06","upperLimit":"26.49"},{"groupId":"OG001","value":"10.53","lowerLimit":"2.94","upperLimit":"24.80"}]}]},{"title":"CD8+ ENV Pol gag PP IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.04","lowerLimit":"66.25","upperLimit":"84.17"},{"groupId":"OG001","value":"81.25","lowerLimit":"67.37","upperLimit":"91.05"},{"groupId":"OG002","value":"3.23","lowerLimit":"0.08","upperLimit":"16.70"}]}]},{"title":"CD8+ ENV Pol gag PP IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.43","lowerLimit":"61.00","upperLimit":"80.41"},{"groupId":"OG001","value":"77.50","lowerLimit":"61.55","upperLimit":"89.16"},{"groupId":"OG002","value":"3.70","lowerLimit":"0.09","upperLimit":"18.97"}]}]},{"title":"CD8+ ENV Pol gag PP IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.62","lowerLimit":"58.25","upperLimit":"79.47"},{"groupId":"OG001","value":"65.79","lowerLimit":"48.65","upperLimit":"80.37"},{"groupId":"OG002","value":"4.00","lowerLimit":"0.10","upperLimit":"20.35"}]}]},{"title":"CD8+ ENV gag PP ANY IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.58","lowerLimit":"29.75","upperLimit":"50.08"},{"groupId":"OG001","value":"39.58","lowerLimit":"25.77","upperLimit":"54.73"},{"groupId":"OG002","value":"3.23","lowerLimit":"0.08","upperLimit":"16.70"}]}]},{"title":"CD8+ ENV gag PP ANY IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.91","lowerLimit":"22.75","upperLimit":"44.40"},{"groupId":"OG001","value":"31.58","lowerLimit":"17.50","upperLimit":"48.65"},{"groupId":"OG002","value":"4.00","lowerLimit":"0.10","upperLimit":"20.35"}]}]},{"title":"CD8+ Pol PP (Mos1) IFNg+ /IL2+ Wk 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.50","lowerLimit":"52.03","upperLimit":"72.18"},{"groupId":"OG001","value":"62.50","lowerLimit":"47.35","upperLimit":"76.05"}]}]},{"title":"CD8+ Pol PP (Mos1) IFNg+ /IL2+ Wk 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.95","lowerLimit":"44.16","upperLimit":"65.40"},{"groupId":"OG001","value":"50.00","lowerLimit":"33.80","upperLimit":"66.20"}]}]},{"title":"CD8+ Pol PP (Mos1) IFNg+ /IL2+ Wk 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.90","lowerLimit":"40.36","upperLimit":"63.29"},{"groupId":"OG001","value":"36.84","lowerLimit":"21.81","upperLimit":"54.01"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With T-cell Development","description":"As per change in planned analysis, this outcome measure was not performed since it was no longer considered relevant to interpret the immunogenicity of the vaccines.","populationDescription":"The PPI analysis set included all participants who had received at least first three vaccinations, according to protocol-specified vaccination schedule (+/- 2 weeks), had at least 1 measured post-dose blood sample collected and were not diagnosed with HIV infection during the study.","reportingStatus":"POSTED","timeFrame":"Up to Week 264","groups":[{"id":"OG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264)."},{"id":"OG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72."},{"id":"OG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to Week 264","description":"The full analysis set (FAS) included of all participants who were randomized and who received atleast one dose of study vaccine. One participant had serious adverse event during main study and long-term extension period. This participant has only been counted once in the adverse event section","eventGroups":[{"id":"EG000","title":"Tetravalent Ad26.Mos4.HIV Vaccine","description":"Participants received adenovirus serotype 26-Mosaic-Human Immunodeficiency Virus (Ad26.Mos4.HIV) vaccine 5\\*10\\^10 virus particles (vp) via Intramuscular (IM) injection at Weeks (Wks) 0 and 12. At Weeks 24 and 48, participants received 5\\*10\\^10 vp Ad26.Mos4.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 micrograms (mcg) of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72. Participants who had received all 4 vaccinations and were negative for HIV infection at Week 72 were included in an optional Long-term Extension (LTE) phase (up to Week 264).","deathsNumAffected":0,"deathsNumAtRisk":110,"seriousNumAffected":9,"seriousNumAtRisk":110,"otherNumAffected":37,"otherNumAtRisk":110},{"id":"EG001","title":"Trivalent Ad26.Mos.HIV Vaccine","description":"Participants received Ad26.Mos4.HIV vaccine 5\\*10\\^10 vp via IM injection at Weeks 0 and 12. At Weeks 24 and 48 participants received 5\\*10\\^10 vp Ad26.Mos.HIV vaccine and HIV Clade C glycoprotein 140 (gp140) vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) as an IM injection. Participants were followed up till Week 72.","deathsNumAffected":0,"deathsNumAtRisk":55,"seriousNumAffected":0,"seriousNumAtRisk":55,"otherNumAffected":22,"otherNumAtRisk":55},{"id":"EG002","title":"Placebo","description":"Participants received placebo matching to either Ad26.Mos4.HIV or Ad26.Mos.HIV as 0.5 mL via IM injection at Weeks 0 and 12, and placebo matching to Clade C gp 140/aluminum phosphate adjuvant as 0.5 mL via IM injection at Weeks 24 and 48. The placebo arms were pooled as there were no differences in the individuals randomized to either of the placebo groups. Participants were followed up till Week 72.","deathsNumAffected":0,"deathsNumAtRisk":33,"seriousNumAffected":0,"seriousNumAtRisk":33,"otherNumAffected":15,"otherNumAtRisk":33}],"seriousEvents":[{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Covid-19 Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Ankle Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Rheumatoid Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Acoustic Neuroma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Abortion Spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Bipolar I Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Lymphoedema","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]}],"otherEvents":[{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":110},{"groupId":"EG001","numAffected":3,"numAtRisk":55},{"groupId":"EG002","numAffected":1,"numAtRisk":33}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":110},{"groupId":"EG001","numAffected":9,"numAtRisk":55},{"groupId":"EG002","numAffected":10,"numAtRisk":33}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":110},{"groupId":"EG001","numAffected":4,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Viral Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":110},{"groupId":"EG001","numAffected":2,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Muscle Strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":55},{"groupId":"EG002","numAffected":2,"numAtRisk":33}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":110},{"groupId":"EG001","numAffected":2,"numAtRisk":55},{"groupId":"EG002","numAffected":3,"numAtRisk":33}]},{"term":"Haemoglobin Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":3,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":110},{"groupId":"EG001","numAffected":3,"numAtRisk":55},{"groupId":"EG002","numAffected":0,"numAtRisk":33}]},{"term":"Oropharyngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":110},{"groupId":"EG001","numAffected":3,"numAtRisk":55},{"groupId":"EG002","numAffected":1,"numAtRisk":33}]},{"term":"Dermatitis Contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":1,"numAtRisk":55},{"groupId":"EG002","numAffected":2,"numAtRisk":33}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"In this study, the ability to generalize the study outcomes is limited to populations that were included."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days."},"pointOfContact":{"title":"Clinical Franchise Leader","organization":"Janssen Vaccines & Prevention B.V","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-10-28","uploadDate":"2023-04-25T06:58","filename":"Prot_000.pdf","size":6027053},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-05-02","uploadDate":"2023-04-25T06:58","filename":"SAP_001.pdf","size":932760}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"}},"hasResults":true}